Company to hold one-on-one meetings with multinational drugmakers and investors on GI-214 and other pipeline candidates

CEO Chang Myung-ho vows to 'produce tangible results' by deepening licensing talks for each pipeline

A poster for the 2026 Jefferies Global Healthcare Conference, to be held in London. [GI Innovation]
A poster for the 2026 Jefferies Global Healthcare Conference, to be held in London. [GI Innovation]

GI Innovation, a developer of innovative new drugs, will attend Europe's largest healthcare investment event to advance licensing and partnership talks with global pharmaceutical companies.

The company announced Wednesday that it will participate in the 2026 Jefferies Global Healthcare Conference, to be held in London from Nov. 16 to Nov. 19.

Hosted annually by global investment bank Jefferies, the conference is the largest healthcare investment gathering in Europe. Pharmaceutical and biotech companies from around the world convene alongside major institutional investors to share the latest industry trends and explore strategic cooperation, including investment opportunities and co-development arrangements.

During the event, GI Innovation will hold one-on-one partnering meetings with multiple global pharmaceutical companies and new institutional investors, covering GI-214 — its lead pipeline candidate — and several other drug candidates under ongoing discussion. The company said it plans to advance licensing negotiations and broadly explore opportunities to attract global investment.

"We have a number of individual meetings scheduled at this conference covering multiple pipelines," Chief Executive Chang Myung-ho said. "We will deepen the licensing discussions we have been building and conduct in-depth negotiations tailored to the development stage and characteristics of each pipeline, with the goal of producing tangible commercialization results."

The participation builds on the global drug development capabilities GI Innovation demonstrated through its recent clinical collaboration with Johnson & Johnson, and aims to put early-stage licensing negotiations for GI-214 and other follow-on pipeline candidates firmly on track with European investors and major pharmaceutical companies.


silverpaper@heraldcorp.com